EGElisabeth Gjefsen

Elisabeth Gjefsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisabeth Gjefsen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply

    by Elisabeth Gjefsen, John A. Zwart, Lars C. Bråten, Ansgar Espeland, Guro L. Goll, Kjersti Storheim


  • Open Access

    Modic Change Edema in Chronic Low Back Pain Treated With Infliximab or Placebo

    by Magnhild Hammersland Dagestad, Nils Vetti, Lars Christian Haugli Bråten, Elisabeth Gjefsen, Lars Grøvle, Kristina Gervin, Anne Julsrud Haugen, Gunnstein Bakland, Gunn Hege Marchand, Thomas Kadar, et al.

    Study Design.: Randomized trial. Objective.: To assess whether infliximab is superior to placebo in reducing Modic change (MC) edema, and whether MC edema or apparent diffusion coefficient (ADC) values of MCs modify the effect of infliximab on disability or low back pain (LBP). Summary of Background Data.: In the present BackToBasic trial, infliximab did not reduce disability or LBP at five months follow-up in patients with chronic LBP and MC type 1. The effect on MC edema and in edema-defined subgroups is unknown. Materials and Methods.: Patients with chronic LBP and type 1 MCs were randomized to receive four infliximab infusions or placebo over 98 days. MC edema was assessed using short tau inversion recovery imaging. Primary edema variables were maximum baseline edema volume (Volmax) ≥25% of vertebral body marrow (yes/no) and reduced edema at six months (yes/no). Maximum MC-related ADC value (0%–100%) was measured at baseline. Outcomes at five months were the Oswestry disability index (ODI, 0–100, primary outcome) and LBP intensity (0–10). The analyses included logistic regression and linear mixed-effects models. Results.: One hundred twenty-eight patients (mean age 43 yr, 84 women) were included, of which 78 were treated per protocol (PP). The odds ratio for reduced MC edema at six months in the infliximab versus placebo group was 2.2 (95% CI: 0.8–5.8; P=0.12) in the primary PP analysis and 2.1 (95% CI: 1.02–4.5; P=0.04) in the total sample. Neither MC edema nor ADC values modified the effect of infliximab on ODI or LBP intensity. At five months, the effect in the Volmax ≥25% group was -4.2 ODI points (95% CI: -11.4 to 3.1; primary PP analysis). Conclusion.: Infliximab had no clinically relevant edema reducing effect. MC edema did not modify the effect of infliximab on disability or LBP, nor did the MC-related ADC value. Level of Evidence.: Level II.


  • Open Access

    Gene Expression Correlates with Disability and Pain Intensity in Patients with Chronic Low Back Pain and Modic Changes in a Sex-Specific Manner

    by Maria Dehli Vigeland, Siri Tennebø Flåm, Magnus Dehli Vigeland, Manuela Zucknick, Monica Wigemyr, Lars Christian Haugli Bråten, Elisabeth Gjefsen, John-Anker Zwart, Kjersti Storheim, Linda Margareth Pedersen, et al.

    Chronic low back pain (cLBP) lacks clear physiological explanations, and the treatment options are of limited effect. We aimed to elucidate the underlying biology of cLBP in a subgroup of patients with Modic changes type I (suggestive of inflammatory vertebral bone marrow lesions) by correlating gene expression in blood with patient-reported outcomes on disability and pain intensity and explore sex differences. Patients were included from the placebo group of a clinical study on patients with cLBP and Modic changes. Blood was collected at the time of inclusion, after three months, and after one year, and gene expression was measured at all time points by high-throughput RNA sequencing. The patients reported disability using the Roland–Morris Disability Questionnaire, and pain intensity was assessed as a mean of three scores on a 0–10 numeric rating scale: current LBP, worst LBP within the last two weeks, and mean LBP within the last two weeks. The gene expression profiles were then correlated to the reported outcomes. Changes in gene expression over time correlated significantly with changes in both disability and pain. The findings showed distinct patterns in men and women, with negligible overlap in correlated genes between the sexes. The genes involved were enriched in immunological pathways, particularly T cell receptor complex and immune responses related to neutrophils. Several of the genes harbour polymorphisms that previously have been found to be associated with chronic pain. Taken together, our results indicate gender differences in the underlying biology of disability and pain intensity in patients with low back pain.


  • Open Access

    Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low‐Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial

    by Elisabeth Gjefsen, Lars C. Bråten, Erica Ponzi, Magnhild H. Dagestad, Gunn H. Marchand, Thomas Kadar, Gunnstein Bakland, Anne J. Haugen, Fredrik Granviken, Tonje W. Flørenes, et al.

    Objective: The efficacy of tumor necrosis factor inhibitors for treating chronic low‐back pain with Modic changes is uncertain. This study investigated the superiority of infliximab over placebo in patients with Modic type 1 changes.Methods: In this multicenter, randomized, triple‐blind, placebo‐controlled trial, patients aged 18 to 65 years with moderate to severe chronic low‐back pain and Modic type 1 changes were enrolled from five Norwegian public hospitals between January 2019 and October 2022. Participants were randomly assigned to four intravenous infusions of 5 mg/kg infliximab or placebo. The primary outcome was difference in change in the Oswestry Disability Index (ODI) score from baseline to five months. Secondary outcomes included changes in low‐back pain intensity, disability, and health‐related quality of life. A linear mixed model was used for efficacy analyses.Results: A total of 128 patients (mean age 43 years, 65.6% women) participated (64 in each group). All patients who received at least one dose of the allocated infusion were included in the primary analyses. The average ODI score (±SD) change was −7.0 (±9.7) in the group who received infliximab and −6.4 (±10.4) in the group who received placebo. The difference in the ODI score change between the two groups was 1.3 ODI points (95% confidence interval −2.1 to 4.6, P = 0.45). Analyses showed no effect of infliximab compared to placebo on secondary outcomes. Adverse event rates were similar between groups.Conclusion: Infliximab did not demonstrate superiority over placebo in reducing pain‐related disability in patients with moderate to severe chronic low‐back pain with Modic type 1 changes at five months. image


  • Open Access

    Long-Term Use of Amoxicillin Is Associated with Changes in Gene Expression and DNA Methylation in Patients with Low Back Pain and Modic Changes

    by Maria Dehli Vigeland, Siri Tennebø Flåm, Magnus Dehli Vigeland, Ansgar Espeland, Manuela Zucknick, Monica Wigemyr, Lars Christian Haugli Bråten, Elisabeth Gjefsen, John-Anker Zwart, Kjersti Storheim, et al.

    Long-term antibiotics are prescribed for a variety of medical conditions, recently including low back pain with Modic changes. The molecular impact of such treatment is unknown. We conducted longitudinal transcriptome and epigenome analyses in patients (n = 100) receiving amoxicillin treatment or placebo for 100 days in the Antibiotics in Modic Changes (AIM) study. Gene expression and DNA methylation were investigated at a genome-wide level at screening, after 100 days of treatment, and at one-year follow-up. We identified intra-individual longitudinal changes in gene expression and DNA methylation in patients receiving amoxicillin, while few changes were observed in patients receiving placebo. After 100 days of amoxicillin treatment, 28 genes were significantly differentially expressed, including the downregulation of 19 immunoglobulin genes. At one-year follow-up, the expression levels were still not completely restored. The significant changes in DNA methylation (n = 4548 CpGs) were mainly increased methylation levels between 100 days and one-year follow-up. Hence, the effects on gene expression occurred predominantly during treatment, while the effects on DNA methylation occurred after treatment. In conclusion, unrecognized side effects of long-term amoxicillin treatment were revealed, as alterations were observed in both gene expression and DNA methylation that lasted long after the end of treatment.


  • Open Access

    Cytokine Patterns as Predictors of Antibiotic Treatment Effect in Chronic Low Back Pain with Modic Changes: Subgroup Analyses of a Randomized Trial (AIM Study)

    by Lars Christian Haugli Bråten, Elisabeth Gjefsen, Kristina Gervin, Are Hugo Pripp, Jan Sture Skouen, Elina Schistad, Linda Margareth Pedersen, Monica Wigemyr, Kaja Kristine Selmer, Hans Christian Dalsbotten Aass, et al.

    Objective: Randomized trials testing the effect of antibiotics for chronic low back pain (LBP) with vertebral bone marrow changes on MRI (Modic changes) report inconsistent results. A proposed explanation is subgroups with low grade discitis where antibiotics are effective, but there is currently no method to identify such subgroups. The objective of the present study was to evaluate whether distinct patterns of serum cytokine levels predict any treatment effect of oral amoxicillin at one-year follow-up in patients with chronic low back pain and Modic changes at the level of a previous lumbar disc herniation. Design: We used data from an overpowered, randomized, placebo-controlled trial (the AIM study) that tested 100 days of oral 750 mg amoxicillin vs placebo three times daily in hospital outpatients with chronic (> 6 months) LBP with pain intensity ≥ 5 on a 0– 10 numerical rating scale and Modic changes type 1 (oedema type) or 2 (fatty type). We measured serum levels of 40 inflammatory cytokines at baseline and analysed six predefined potential predictors of treatment effect based on cytokine patterns in 78 randomized patients; three analyses with recursive partitioning, one based on cluster analysis and two based on principal component analyses. The primary outcome was the Roland–Morris Disability Questionnaire score at one-year follow-up in the intention to treat population. The methodology and overall results of the AIM study were published previously. Results: The 78 patients were 25– 62 years old and 47 (60%) were women. None of the three recursive partitioning analyses resulted in any suggested subgroups. Of all main analyses, the largest effect estimate (mean difference between antibiotic and placebo groups) was seen in a subgroup not predefined as of main interest (Cluster category 3+4; − 2.0, 95% CI: − 5.2– 1.3, RMDQ points; p-value for interaction 0.54). Conclusion: Patterns of inflammatory serum cytokine levels did not predict treatment effect of amoxicillin in patients with chronic LBP and Modic changes. Clinical Trial Registration Number: ClinicalTrials.gov (identifier: NCT02323412).


  • Open Access

    Longitudinal changes of serum cytokines in patients with chronic low back pain and Modic changes

    by E. Gjefsen, K. Gervin, L.C.H. Bråten, G.L. Goll, H.C.D. Aass, E.I. Schistad, M. Wigemyr, L.M. Pedersen, J.S. Skouen, M D Vigeland, et al.


  • Open Access

    Minimal important change was on the lower spectrum of previous estimates and responsiveness was sufficient for core outcomes in chronic low back pain

    by Lars Christian Haugli Bråten, Lars Grøvle, Monica Wigemyr, Maja Wilhelmsen, Elisabeth Gjefsen, Ansgar Espeland, Anne Julsrud Haugen, Jan Sture Skouen, Jens Ivar Brox, John-Anker Zwart, et al.


  • Open Access

    Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes

    by Elisabeth Gjefsen, Kristina Gervin, Guro Goll, Lars Christian Haugli Bråten, Monica Wigemyr, Hans Christian D Aass, Maria Dehli Vigeland, Elina Schistad, Linda Margareth Pedersen, Are Hugo Pripp, et al.

    Background Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) have been proposed as a distinct LBP phenotype, and inflammatory mediators may be involved in the development of MCs. Objectives To identify possible serum biomarkers for LBP in patients with MCs. Methods In this case control study serum levels of 40 cytokines were compared between patients with LBP and MC type 1 (n=46) or type 2 (n=37) and healthy controls (n=50). Results Analyses identified significantly higher levels of six out of 40 cytokines in the MC type 1 group (MC1), and five in the MC type 2 group (MC2) compared with healthy controls. Six cytokines were moderately correlated with pain. Principal component analyses revealed clustering and separation of patients with LBP and controls, capturing 40.8% of the total variance, with 10 cytokines contributing to the separation. Macrophage migration inhibitory factor (MIF) alone accounted for 92% of the total contribution. Further, receiver operating characteristics analysis revealed that MIF showed an acceptable ability to distinguish between patients and controls (area under the curve=0.79). Conclusions These results suggest that cytokines may play a role in LBP with MCs. The clinical significance of the findings is unknown. MIF strongly contributed to clustering of patients with LBP with MCs and controls, and might be a biomarker for MCs. Ultimately, these results may guide future research on novel treatments for this patient group.


  • Open Access

    The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

    by Elisabeth Gjefsen, Lars Christian Haugli Bråten, Guro Løvik Goll, Monica Wigemyr, Nils Bolstad, Morten Valberg, Elina Iordanova Schistad, Gunn Hege Marchand, Fredrik Granviken, Kaja Kristine Selmer, et al.

    Background: Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as Modic changes on magnetic resonance imaging may represent a subgroup within the low back pain population. There is evidence for inflammatory mediators being involved in development of Modic changes; hence, suppression of inflammation could be a treatment strategy for these patients. This study examines the effect of anti-inflammatory treatment with the TNF-α inhibitor infliximab in patients with chronic low back pain and Modic changes. Methods/design: The BackToBasic trial is a multicenter, double blind, randomized controlled trial conducted at six hospitals in Norway, comparing intravenous infusions with infliximab with placebo. One hundred twenty-six patients aged 18–65 with chronic low back pain and type 1 Modic changes will be recruited from secondary care outpatients’ clinics. The primary outcome is back pain-specific disability at day 154 (5 months). The study is designed to detect a difference in change of 10 (SD 18) in the Oswestry Disability Index at day 154/ 5 months. The study also aims to refine MRI-assessment, investigate safety and cost-effectiveness and explore the underlying biological mechanisms of Modic changes. Discussion: Finding treatments that target underlying mechanisms could pose new treatment options for patients with low back pain. Suppression of inflammation could be a treatment strategy for patients with low back pain and Modic changes. This paper presents the design of the BackToBasic study, where we will assess the effect of an anti-inflammatory treatment versus placebo in patients with chronic low back pain and type 1 Modic changes. The study is registered at ClinicalTrials.gov under the identifier NCT03704363. The EudraCT Number: 2017–004861-29.